Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin + Cytarabine in Untreated AML
NCT02658487Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Mar 2016
- Primary completion
- Apr 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of vosaroxin in acute myeloid leukemia (AML), sponsored by Vanderbilt-Ingram Cancer Center. Started Mar 2016; status: completed.
02
Drugs
vosaroxin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02658487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658487.